Ann Pediatr Endocrinol Metab.  2015 Sep;20(3):136-142. 10.6065/apem.2015.20.3.136.

Metabolic effects of polycystic ovary syndrome in adolescents

• Han Y
• Kim HS
• Lee HJ
• Oh JY
• Sung YA

• KMID: 2150389
• DOI: http://doi.org/10.6065/apem.2015.20.3.136

Abstract

PURPOSE
Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenic anovulation in women of reproductive age. We investigated the metabolic effects of lean and overweight adolescents with PCOS.
METHODS
Anthropometric measurements and biochemical parameters were evaluated in 49 adolescents with PCOS and 40 age- and body mass index (BMI)-matched controls. We further divided both PCOS and control groups into those having BMI within the normal range of less than 85th percentile and those being overweight and obese with a BMI greater than 85th percentile.
RESULTS
Hemoglobin, gamma-glutamyl transferase (r-GT), total cholesterol, low-density lipoprotein-cholesterol and 2-hour postglucose load plasma insulin levels were significantly elevated in the lean PCOS group than in the lean control group. In the overweight/obese PCOS group, hemoglobin and r-GT levels were significantly elevated than in the overweight/obese control group. In the normal weight group, none of the subjects had metabolic syndrome according to the Adult Treatment Panel III criteria, but the incidence of metabolic syndrome in the overweight/obese PCOS group was 8.3% and that in the overweight/obese control group was 6.7%.
CONCLUSION
PCOS in adolescents causes metabolic abnormalities, underscoring the importance of early diagnosis of PCOS in oligomenorrheic adolescents.

Keyword

Polycystic ovary syndrome; Metabolic syndrome; Insulin resistance

MeSH Terms

Adolescent*
Adult
Anovulation
Body Mass Index
Cholesterol
Early Diagnosis
Female
Humans
Incidence
Insulin
Insulin Resistance
Overweight
Plasma
Polycystic Ovary Syndrome*
Reference Values
Transferases
Cholesterol
Insulin
Transferases

Figure

• 

  Fig. 1 Comparison of fasting plasma insulin (FPI) and 2-hour postglucose load plasma insulin (2h-PI). 2h-PI was significantly elevated in the lean polycystic ovary syndrome (PCOS) group than in the lean control group. *P<0.05.

Reference

1. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998; 83:3078–3082. PMID: 9745406.

2. Byun EK, Kim HJ, Oh JY, Hong YS, Sung YA. The prevalence of polycystic ovary syndrome in college students from Seoul. J Korean Soc Endocrinol. 2005; 20:120–126.

3. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In : Dunaif A, Givens JR, Haseltine F, Merriam GR, editors. Polycystic ovary syndrome. Boston: Blackwell Scientific Publications;1992. p. 377–384.

4. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004; 19:41–47. PMID: 14688154.

5. Coviello AD, Legro RS, Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab. 2006; 91:492–497. PMID: 16249280.

6. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism. 2003; 52:908–915. PMID: 12870169.

7. Pasquali R, Casimirri F. The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women. Clin Endocrinol (Oxf). 1993; 39:1–16. PMID: 8348699.

8. Norman RJ, Masters L, Milner CR, Wang JX, Davies MJ. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod. 2001; 16:1995–1998. PMID: 11527911.

9. Manco M, Castagneto-Gissey L, Arrighi E, Carnicelli A, Brufani C, Luciano R, et al. Insulin dynamics in young women with polycystic ovary syndrome and normal glucose tolerance across categories of body mass index. PloS One. 2014; 9:e92995. PMID: 24705280.

10. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999; 84:3666–3672. PMID: 10523012.

11. Escobar-Morreale HF, Carmina E, Dewailly D, Gambineri A, Kelestimur F, Moghetti P, et al. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the androgen excess and polycystic ovary syndrome society. Hum Reprod Update. 2012; 18:146–170. PMID: 22064667.

12. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001; 285:2486–2497. PMID: 11368702.

13. Dunaif A. Insulin action in the polycystic ovary syndrome. Endocrinol Metab Clin North Am. 1999; 28:341–359. PMID: 10352922.

14. Silfen ME, Denburg MR, Manibo AM, Lobo RA, Jaffe R, Ferin M, et al. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents. J Clin Endocrinol Metab. 2003; 88:4682–4688. PMID: 14557441.

15. Grulet H, Hecart AC, Delemer B, Gross A, Sulmont V, Leutenegger M, et al. Roles of LH and insulin resistance in lean and obese polycystic ovary syndrome. Clin Endocrinol (Oxf). 1993; 38:621–626. PMID: 8334748.

16. Dunaif A. Insulin Resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997; 18:774–800. PMID: 9408743.

17. Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1985; 61:946–951. PMID: 4044782.

18. Sozen I, Arici A. Hyperinsulinism and its interaction with hyperandrogenism in polycystic ovary syndrome. Obstet Gynecol Surv. 2000; 55:321–328. PMID: 10804539.

19. Diamanti-Kandarakis E, Papavassiliou AG, Kandarakis SA, Chrousos GP. Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metab. 2007; 18:280–285. PMID: 17692530.

20. Dejager S, Pichard C, Giral P, Bruckert E, Federspield MC, Beucler I, et al. Smaller LDL particle size in women with polycystic ovary syndrome compared to controls. Clin Endocrinol (Oxf). 2001; 54:455–462. PMID: 11318780.

21. Orio F Jr, Palomba S, Spinelli L, Cascella T, Tauchmanovà L, Zullo F, et al. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab. 2004; 89:3696–3701. PMID: 15292291.

22. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999; 84:165–169. PMID: 9920077.

23. Arslanian SA, Lewy VD, Danadian K. Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and β-cell dysfunction and risk of cardiovascular disease. J Clin Endocrinol Metab. 2001; 86:66–71. PMID: 11231980.

24. Edman CD, MacDonald PC. Effect of obesity on coriversion of plasma androstenedione to estrone in ovulatory and anovulatory young women. Am J Obstet Gynecol. 1978; 130:456–461. PMID: 629290.

25. Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 1991; 72:83–89. PMID: 1898744.

26. Economou F, Xyrafis X, Livadas S, Androulakis II, Argyrakopoulou G, Christakou CD, et al. In overweight/obese but not in normal-weight women, polycystic ovary syndrome is associated with elevated liver enzymes compared to controls. Hormones (Athens). 2009; 8:199–206. PMID: 19671519.

27. Al-Hakeim HK. Correlation Between Iron Status Parameters and Hormone Levels in Women with Polycystic Ovary Syndrome. Clin Med Insights Womens Health. 2012; 5:1–8.

28. Supriya P, Bitla A, Prasad NR, Rajagopal G, Rao AM, Suchitra M, et al. Body iron status and association with hyperinsulinaemia and hyperandrogenism in non-obese Indian women with polycystic ovarian syndrome. J Clin Sci Res. 2012; 1:2–7.

29. Berria R, Gastaldelli A, Lucidi S, Belfort R, De Filippis E, Easton C, et al. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome. Clin Pharmacol Ther. 2006; 80:105–114. PMID: 16890572.

30. Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab. 2008; 93:914–919. PMID: 18160461.

31. Claustres M, Sultan C. Androgen and erythropoiesis: evidence for an androgen receptor in erythroblasts from human bone marrow cultures. Horm Res. 1988; 29:17–22. PMID: 3260889.

32. Yip R, Parvanta I, Cogswell ME, McDonnell SM, Bowman BA, Grummer-Strawn LM, et al. Recommendations to prevent and control iron deficiency in the United States. MMWR Recomm Rep. 1998; 1–29.

33. Bitzer J, Sultan C, Creatsas G, Palacios S. Gynecological care in young women: a high-risk period of life. Gynecol Endocrinol. 2014; 30:542–548. PMID: 24819317.

34. Friedland O, Nemet D, Gorodnitsky N, Wolach B, Eliakim A. Obesity and lipid profiles in children and adolescents. J Pediatr Endocrinol Metab. 2002; 15:1011–1016. PMID: 12199328.

35. Steinberger J, Moorehead C, Katch V, Rocchini AP. Relationship between insulin resistance and abnormal lipid profile in obese adolescents. J Pediatr. 1995; 126:690–695. PMID: 7751990.

36. Park HR, Choi Y, Lee HJ, Oh JY, Hong YS, Sung YA. The metabolic syndrome in young Korean women with polycystic ovary syndrome. Diabetes Res Clin Pract. 2007; 77(Suppl 1):S243–S246. PMID: 17610984.

37. Chae SJ, Kim JJ, Choi YM, Hwang KR, Jee BC, Ku SY, et al. Clinical and biochemical characteristics of polycystic ovary syndrome in Korean women. Hum Reprod. 2008; 23:1924–1931. PMID: 18579512.

38. Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med. 2000; 132:989–993. PMID: 10858183.

39. Macut D, Micic D, Cvijovic G, Sumarac M, Kendereski A, Zoric S, et al. Cardiovascular risk in adolescent and young adult obese females with polycystic ovary syndrome(PCOS). J Pediatr Endocrinol Metab. 2001; 14(Suppl 5):1353–1359. PMID: 11964034.

40. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013; 98:4565–4592. PMID: 24151290.